[4-[(5-bromo-1H-indol-2-yl)sulfonyl]piperazin-1-yl]-(6-pyridin-4-ylpyridin-3-yl)methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [4-[(5-bromo-1H-indol-2-yl)sulfonyl]piperazin-1-yl]-(6-pyridin-4-ylpyridin-3-yl)methanone
• 化学式: C₂₃H₂₀BrN₅O₃S
• 分子量: 526.4
• InChiKey: YFNBXESYHBODNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• HETEROCYCLIC DERIVATIVES AS INHIBITORS OF FACTOR XA
  申请人：AstraZeneca AB

  公开号：EP1150974A1

  公开（公告）日：2001-11-07
• US6723723B1
  申请人：——

  公开号：US6723723B1

  公开（公告）日：2004-04-20
• [EN] HETEROCYCLIC DERIVATIVES AS INHIBITORS OF FACTOR XA<br/>[FR] DERIVES HETEROCYCLIQUES FAISANT OFFICE D'INHIBITEURS DU FACTEUR XA
  申请人：ASTRAZENECA UK LTD

  公开号：WO2000047573A1

  公开（公告）日：2000-08-17

  The invention relates to heterocyclic derivatives, or pharmaceutically-acceptable salts thereof, of formula (I) wherein: A is an optionally substituted 5- or 6-membered monocyclic aromatic ring containing 1, 2 or 3 ring heteroatoms selected from oxygen, nitrogen and sulphur atoms; which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.